Vascular homing peptides with cell-penetrating properties

Current Pharmaceutical Design

Volumn 11, Issue 28, 2005, Pages 3655-3660

  Ruoslahti, E ^a   Duza, T ^a   Zhang, L ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Angiogenesis; Endothelial cells; Lymphatics; Nucleolin; Phage display; Tat peptide; Tumor vasculature

Indexed keywords

ARGININE; ASPARAGINE; ASPARTIC ACID; BASIC FIBROBLAST GROWTH FACTOR; BIOTIN; CELL PENETRATING PEPTIDE; COMPLEMENTARY DNA; DOXORUBICIN; FIBRONECTIN; FLUORESCEIN; GLYCINE; HEPARAN SULFATE; MICROSOMAL AMINOPEPTIDASE; MIDKINE; MOLECULAR MARKER; NUCLEOLIN; PENETRATIN; PEPTIDE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN ANTIBODY; PROTEIN CGKRK; PROTEIN DERIVATIVE; PROTEIN F3; PROTEIN LYP 1; PROTEIN VP22; RHODAMINE; RIBOSOME RNA; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER GROWTH; CELL DIFFERENTIATION; CELL LABELING; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; ENDOTHELIUM CELL; EX VIVO STUDY; HUMAN; IN VIVO STUDY; INTERNALIZATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN TRANSPORT; REVIEW; TARGET CELL; TUMOR VASCULARIZATION; VASCULAR TISSUE; VIRAL GENE THERAPY;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD VESSELS; CELL MEMBRANE; HUMANS; MYOCYTES, SMOOTH MUSCLE; NEOPLASMS; PEPTIDE LIBRARY; PEPTIDES; RECEPTORS, CELL SURFACE; REGIONAL BLOOD FLOW;

EID: 27744532423     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774580787     Document Type: Review

References (39)

1. Ruoslahti E. Specialization of tumour vasculature. Nature Rev Cancer 2002; 2: 83-90.
2. Alitalo K, Carmeliet P. Molecular mechanism of lymphangiogenesis in health and disease. Cancer Cell 2002; 1: 219-27.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100: 57-70.
4. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 2002; 8: 751-5.
5. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380: 364-6.
6. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-90.
7. Hoffman JA, Giraudo E, Singh M, Zhang L, Inoue K Porkka K, et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 2003; 4: 383-91.
8. Joyce JA, Laakkonen P, Bernasconi K Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2003; 4: 393-403.
9. Ruoslahti E, Rajotte D. An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol 2000; 18: 813-27.
10. Porkka K, Laakkonen P, Hoffman JA, Bernasconi M, Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci USA 2002; 99: 7444-9.
11. Langel Ü. Cell-Penetrating Peptides: Processes and Applications., CRC Press: Boca Raton, Florida 2002.
12. Essler M, Ruoslahti E. Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci USA 2002; 99: 2252-7.
13. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 2002; 99: 1527-31.
14. Hoffman J, Laakkonen P, Porkka K, Bernasconi M, Ruoslahti E. In vivo and ex vivo selections using phage-displayed libraries, Oxford University Press 2004.
15. Jacobson BS, Stolz DB, Schnitzer JE. Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease. Nat Med 1996; 2: 482-4.
16. Ding BS, Zhou YJ, Chen XY, Zhang J, Zhang PX, Sun ZY, Tan X-Y, Liu JN. Lung endothelium targeting for pulmonary embolism thrombolysis. Circulation 2003; 108: 2892-8.
17. Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, et al. Subtractive proteomic mapping of the endothelial Wace in lung and solid tumours for tissue-specific therapy. Nature 2004; 429: 629-35.
18. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto K Stryhn A, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60: 722-7.
19. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002; 62: 867-74.
20. Ruoslahti E. Fibronectin and its receptors. Annu Rev Biochem 1988; 57: 375-413.
21. Wickham TJ. Targeting adenovirus. Gene Ther 2000; 7: 110-4.
22. Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I, el al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res 2002; 62: 4273-81.
23. Ellerby HM Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999; 5: 1032-8.
24. Christian S, Pilch J, Akerman, ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003; 163: 871-8.
25. Deng JS, Ballou B, Hofmeister JK. Internalization of anti-nucleolin antibody into viable HEp-2 cells. Mol Biol Rep 1996; 23: 191-5.
26. Larrucea S, Gonzalez-Rubio C, Cambronero R Ballou B, Bonay P, Lopez-Granados E, et al. Cellular adhesion mediated by factor J Biol complement inhibitor. Evidence for nucleolin involvement. J Biol Chem 1998; 273: 31718-25.
27. Said EA, Krust B, Nisole: S, Svab J, Briand JP, Hovanessian AG. The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor. J Biol Chem 2002; 277: 37492-502.
28. Sinclair JF, O'Brien AD. Cell surface-localized nucleolin is a eukaryotic receptor for the adhesin intimin-gamma of enterohemorrhagic Escherichia coli O157:H7. J Biol Chem 2002; 277: 2876-85.
29. Borer RA, Lehner CF, Eppenberger HM, Nigg EA, Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 56: 379-90.
30. Yu D, Schwartz MZ, Petryshyn R. Effect of laminin on the nuclear localization of nucleolin in rat intestinal epithelial IEC-6 cells. Biochem Biophys Res Common 19988 247: 2876-85.
31. Shibata Y, Muramatsu T, Hirai M, Inui T, Kimura T, Saito H, et al. Nuclear targeting by the growth factor midkine. Mol Cell Biol 2002; 22: 6788-96.
32. Bonnet H, Filhol O, Truchot I, Brethenou P, Cochet C, Amalric F, et al. Fibroblast growth factor-2 binds to the regulatory beta subunit of CK2 and directly stimulates CK2 activity toward nucleolin. J Biol Chem 1996; 271: 24781-7.
33. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 2002; 277: 2437-43.
34. Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Nad Acad Sci USA 2004; 101: 9381-6.
35. Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A. Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res 2004; 64: 565-71.
36. Chen Y, Xu X, Hong S, Chen J, Liu N, Underhill CB, el al. RGD-Tachyplesin inhibits tumorgrowth. Cancer Res 2001; 61: 2434-8.
37. Brantley-Sieders D,, Parker M, Chen J. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Design 2004; 10(27) 3431-42.
38. Haubner F, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Design 2004; 10(13):1439-55.
39. Stacker SA, Hughes RA, Achen MG. Molecular targeting of lymphatics for therapy. Curr Pharm Design 2004; 10(1):65-74